Turns out, scientists have found a way to control the amount of collagen secreted from cells as its imbalance is linked to various diseases.
According to a study conducted by the Tokyo Institute of Technology, researchers have identified an enzyme that controls how much our cells secrete collagen. The study provides clues to new therapeutic strategies.
Moreover, the findings could facilitate efficient production of collagen for the food, cosmetic and pharmaceutical industries.
All of our cells make and release proteins. The proteins are packaged as 'cargo' in tiny, bubble-like vesicles before being transported outside the cell. This process, known as secretion, is vital to healthy growth and development.
Although many studies have shown how these vesicles, called COPII carriers, handle relatively small-sized cargo, few have focused on the workings of unusually large carriers known to package very large proteins, such as collagen.
Now, a study by researchers including Masayuki Komada and Kohei has identified USP8 as a key enzyme involved in controlling the formation of large collagen carriers.
The team showed that 'switching on' USP8 inhibited the formation of large carriers, and thus reduced collagen secretion. Conversely, switching USP8 off promoted collagen transport, which led to increased collagen secretion.
The findings have big implications for medicine and biotechnology. Excessive collagen secretion in the human body is known to cause organ fibrosis, while too little collagen secretion is associated with bone diseases including cranio-lenticulo-sutural dysplasia (CLSD) and Cole-Carpenter syndrome.
New treatments for these diseases could be developed through a further understanding of USP8's exact mode of action. Such knowledge could also provide new ways of scaling up to commercial production of collagen.
The researchers have demonstrated that the enzyme works by deubiquitinating a protein called Sec31A, a component of the COPII vesicle coat required for protein export.
One particular group of proteins called the USP8-STAM1 complex appears to be responsible for deubiquitinating Sec31A.
The study built on many years of research that has illuminated the versatility of USP8.
"We had previously reported that USP8 regulates pituitary hormone secretion," said Fukushima, referring to a paper published in Nature Genetics in 2015. "In the process of that study, we accidentally found that the USP8-STAM1 complex binds to Sec31."
It was this 'accidental' finding, combined with promising results from other groups in the US that led the team to examine the role of USP8 in the formation of COPII carriers.
In research tracing back more than a decade, Komada and others have clarified the conventional role of USP8 in the regulation of endocytosis5.
"It's very interesting that the same USP8-STAM1 complex has now been shown to play an important role both in the regulation of endocytosis and in secretion," Fukushima said.
The study appears in the journal Biochemical and Biophysical Research Communications.
Disclaimer: No Business Standard Journalist was involved in creation of this content
